New drug shows promise for transplant complication without steroids
NCT ID NCT04294641
First seen Jan 24, 2026 · Last updated May 03, 2026 · Updated 8 times
Summary
This study tested the drug ibrutinib as a first treatment for people newly diagnosed with chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the recipient's body after a stem cell transplant. Ten adults with moderate or severe cGVHD took ibrutinib daily for up to 2 years. The goal was to see if the drug could control the disease without using steroids. Results measured how many patients had a complete or partial response at 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Washington University, School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.